Cardior: Novo to acquire heart failure drug in deal for Cardior
Cardior's therapy is currently in mid-stage testing and should the deal close, Novo plans to start another Phase 2 trial in heart failure.
Read full article »
Cardior is a Germany-based biopharmaceutical company that researches and develops RNA-dependent therapies for the treatment of heart diseases.
Read more